✦ AI AI Company Comparison

Eikon Therapeutics vs Faire — IPO & Funding Comparison

Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.

⚠️
Some data on this page may be outdated. We're verifying.
Eikon Therapeutics: verified Jul 9, 2026. Data for Faire last verified: Jul 3, 2026.
Metric Eikon Therapeutics Faire
Valuation$3.25B$12.4B
Total Funding$771M$1.7B
IPO StatusPrivatePrivate
SectorBiotechnologyE-commerce
StageSeries ASeries H
HeadquartersHayward, CASan Francisco, CA
CEORoger PomerantzMax Rhodes
The IPO Stack Newsletter

Get Tuesday's IPO moves + one deep-dive in your inbox

Scores, valuations, and signals for Eikon Therapeutics, Faire, and 370+ companies. 5-min read every Tuesday.

Eikon Therapeutics

Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.

IndustryBiotechnology
StageSeries A
IPO StatusPrivate
Valuation$3.25B
Total Funding$771M
HeadquartersHayward, CA

Faire

Faire is the wholesale marketplace connecting 700K+ independent retailers with 100K+ emerging brands — the B2B commerce platform for the indie retail economy. Valued at $12.4B with $1.7B raised, Faire processes billions in annual GMV and is the dominant wholesale marketplace globally. IPO candidate as B2B commerce digitisation continues to disrupt traditional wholesale distribution — a $50B+ global market.

IndustryE-commerce
StageSeries H
IPO StatusPrivate
Valuation$12.4B
Total Funding$1.7B
HeadquartersSan Francisco, CA

Get the Full Report on Any Company — One-Time $19

Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.

Get All 375+ Reports — $49/mo

Or buy any single company report for $19

Frequently Asked Questions

What is the Eikon Therapeutics vs Faire valuation in 2026? +

Eikon Therapeutics is valued at $3.25B. Faire is valued at $12.4B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.

Which is more likely to IPO first — Eikon Therapeutics or Faire? +

Eikon Therapeutics is currently private. Faire filed an S-1 in April 2026 and is actively in the IPO pipeline. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.

How much has each company raised in total funding? +

Eikon Therapeutics has raised $771M. Faire has raised $1.7B.

Are Eikon Therapeutics and Faire in the same sector? +

Eikon Therapeutics operates in Biotechnology, while Faire operates in E-commerce.

What are the key differences between Eikon Therapeutics and Faire as investments? +

Eikon Therapeutics is a Biotechnology company valued at $3.25B with $771M raised. Faire is a E-commerce company valued at $12.4B with $1.7B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.

How can I invest in Eikon Therapeutics or Faire before their IPO? +

Accredited investors can access pre-IPO shares in Eikon Therapeutics and Faire through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.